Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giulia Vetere
Observed name:
G. Vetere
Institutions:
Azienda Ospedaliero-Universitaria Careggi,
University of Florence
Observed institutions:
University of Pisa,
University of Modena and Reggio Emilia,
The University of Texas MD Anderson Cancer Center,
Azienda Ospedaliero-Universitaria Careggi,
Azienda Ospedaliera Universitaria Pisana,
University of Florence
show all 6
ORCID:
0009-0007-6301-1267
Observed ORCID:
0009-0007-6301-1267
OpenAlex ID:
A5085054705
Prognostic Value of Malnutrition, Frailty, and Physical Performance in Transthyretin Cardiac Amyloidosis: Insights From a Prospective Multicenter Cohort Study
2025
·
Carlo Fumagalli
, Mattia Zampieri
, et al.
·
Circulation Heart Failure
·
11
732MO Circulating tumour DNA (ctDNA) clearance and correlation with outcome in the INTERCEPT colorectal cancer (CRC) study
2025
·
E. Osterlund
, G. Maddalena
, et al.
·
Annals of Oncology
·
4
Phenotypes of vulnerability and prognosis in older adults with cardiovascular disease
2026
·
Carlo Fumagalli
, Giulia Vetere
, et al.
·
European Journal of Preventive Cardiology
·
1
PDF
19P Circulating tumor DNA (ctDNA) dynamics predict clinical recurrence in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment
2025
·
V. Studiale
, R. Moretto
, et al.
·
Annals of Oncology
·
1
PDF
158TiP Exploiting circulating tumor DNA (ctDNA) to intensify the adjuvant (adj) or post-adj treatment of stage III and high-risk stage II resected colon cancer patients (pts): The ERASE-CRC project by GONO
2024
·
V. Conca
, G. Vetere
, et al.
·
Annals of Oncology
·
1
PDF
SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)
2023
·
M. Germani
, R. Moretto
, et al.
·
Annals of Oncology
·
1
PDF
367P Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings from the PARERE study
2022
·
M.M. Germani
, D. Rossini
, et al.
·
Annals of Oncology
·
1
17P Clinical utility of liquid biopsy in patients with metastatic non-resectable CRC
2025
·
M.M.G. Yousef
, S. Chowdhury
, et al.
·
Annals of Oncology
PDF
112P The presence of liver metastases does not predict resistance to immunotherapy in proficient MMR metastatic colorectal cancer (mCRC): A secondary analysis of the AtezoTRIBE study
2024
·
M. Carullo
, C. Antoniotti
, et al.
·
Annals of Oncology
PDF
53P Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase I TriComB study
2024
·
P. Ciracì
, V. Conca
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
10
Citation count:
20
H-index:
2
I10-index:
1
Year
Topic
Type